Published in Epilepsia on November 01, 2004
Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry (2005) 4.86
Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res (2008) 2.02
Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem (2008) 0.98
Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr (2005) 0.95
Pregnant women with epilepsy in a developing country. Open Neurol J (2011) 0.77
No increase in adverse pregnancy outcomes for women receiving antiepileptic drugs. J Neurol (2009) 0.77
EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. Br J Clin Pharmacol (2016) 0.76
Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. Pharmacoepidemiol Drug Saf (2014) 0.75
Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts. Neurotherapeutics (2016) 0.75
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia (2011) 3.48
Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation (2007) 3.34
Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation (2006) 3.22
Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol (2013) 3.06
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Unifying the definitions of sudden unexpected death in epilepsy. Epilepsia (2011) 2.24
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J (2004) 2.19
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation (2007) 2.15
Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat Genet (2013) 2.11
Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA (2004) 2.02
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J (2004) 1.68
Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation (2005) 1.68
Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J (2008) 1.58
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost (2007) 1.48
Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet (2012) 1.48
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Mortality of epilepsy in developed countries: a review. Epilepsia (2005) 1.44
Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study. Thromb Haemost (2010) 1.42
Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Diabetes Care (2013) 1.42
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Genetic risk estimation by healthcare professionals. Med J Aust (2005) 1.39
DNA analysis of AHI1, NPHP1 and CYCLIN D1 in Joubert syndrome patients from the Netherlands. Eur J Med Genet (2007) 1.39
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
Seated dentistry. Dent Hist (2011) 1.38
Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome. J Cardiovasc Med (Hagerstown) (2006) 1.38
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Mutations in WNT10A are present in more than half of isolated hypodontia cases. J Med Genet (2012) 1.37
Teratogenic effects of antiepileptic drugs. Lancet Neurol (2012) 1.36
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology (2012) 1.32
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol (2002) 1.30
Risk factors for suicide in epilepsy: a case control study. Epilepsia (2002) 1.29
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
The pharmacological treatment of epilepsy in adults. Lancet Neurol (2011) 1.22
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology (2013) 1.18
Oral contraceptives reduce lamotrigine plasma levels. Neurology (2003) 1.18
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit (2003) 1.15
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol (2005) 1.14
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet (2006) 1.14
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
Telemedicine for new neurological outpatients: putting a randomized controlled trial in the context of everyday practice. J Telemed Telecare (2002) 1.08
Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res (2005) 1.08
Exploration of the genetic architecture of idiopathic generalized epilepsies. Epilepsia (2006) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome. Eur J Neurosci (2011) 1.07
Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res (2004) 1.07
Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia (2010) 1.06
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia (2007) 1.06